NCT05917288View on ClinicalTrials.gov

A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 7, 2023

Primary Completion Date

October 30, 2024

Study Completion Date

October 30, 2024

Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL

Belimumab

Belimumab will be administered

DRUG

Standard of care

Standard of care will be administered

Trial Locations (6)

100045

GSK Investigational Site, Beijing

210011

GSK Investigational Site, Nanjing

215007

GSK Investigational Site, Suzhou

310052

GSK Investigational Site, Hangzhou

361006

GSK Investigational Site, Shanghai

410007

GSK Investigational Site, Changsha

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT05917288 - A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter